| Literature DB >> 28100202 |
Kazunori Fujiwara1, Katsuyuki Kawamoto2, Yoko Shimizu3, Takahiro Fukuhara2, Satoshi Koyama2, Hideyuki Kataoka2, Hiroya Kitano2, Hiromi Takeuchi2.
Abstract
BACKGROUND: The reflex cough test is useful for detecting silent aspiration, a risk factor for aspiration pneumonia. However, assessing the risk of aspiration pneumonia requires measuring not only the cough reflex but also cough strength. Currently, no reflex cough testing device is available that can directly measure reflex cough strength. We therefore developed a new testing device that can easily and simultaneously measure cough strength and the time until the cough reflex, and verified whether screening with this new instrument is feasible for evaluating the risk of aspiration pneumonia.Entities:
Keywords: Aspiration pneumonia; Involuntary cough; Peak cough flow; Reflex cough test; Silent aspiration
Mesh:
Substances:
Year: 2017 PMID: 28100202 PMCID: PMC5242037 DOI: 10.1186/s12890-017-0365-y
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Fig. 1Schematic diagram of modified reflex cough test using our new equipment. The new cough reflex testing device consists of a mouthpiece, tube, filter, spirometer (gray arrow), and ultrasound nebulizer (white arrow). The tube is designed as a double pipe (black arrow) with ten holes between the inner and outer pipes. A corrugated tube (white triangle) from the ultrasound nebulizer is connected to the outer pipe, and the spirometer sensor is attached to the inner pipe (black triangle). The microaerosol emitted from the ultrasound nebulizer fills the outer pipe, and is administered to the oral and airway epithelia through the holes and mouthpiece. The cough then passes through the inner pipe to the spirometer sensor
Primary disease of all patients
| Group A | Group B | ||
|---|---|---|---|
| Parkinson disease | 8 | Parkinson disease | 5 |
| hypopharyngeal cancer | 6 | cerebral infarction | 3 |
| cerebral infarction | 5 | multiple system atrophy | 3 |
| multiple system atrophy | 4 | amyotrophic lateral sclerosis | 2 |
| amyotrophic lateral sclerosis | 2 | chordoma | 1 |
| laryngeal cancer | 2 | dementia | 1 |
| oropharyngeal cancer | 2 | encephalomyelitis | 1 |
| progressive supranuclear palsy | 2 | COPD | 1 |
| Wallenberg syndrome | 2 | Gaucher disease | 1 |
| Alzheimer | 1 | myasthenia gravis | 1 |
| aortic aneurysm | 1 | pneumonia | 1 |
| asthma | 1 | recurrent laryngeal nerve palsy | 1 |
| dementia | 1 | ||
| dermatomyositis | 1 | ||
| maxillary cancer | 1 | ||
| mitochondrial myopathy | 1 | ||
| motor neuron disease | 1 | ||
| muscular sarcoidosis | 1 | ||
| myasthenia gravis | 1 | ||
| myotonic dystrophy | 1 | ||
| pontine infarction | 1 | ||
| recurrent laryngeal nerve palsy | 1 | ||
| schizophrenia | 1 | ||
| spinocerebellar degeneration | 1 | ||
| thalamic hemorrhage | 1 |
Fig. 2Peak cough flow of controls and patients with and without AP. The PCF of group B (with AP) was significantly lower than that of group A (without AP) and the control group, while that of group A was significantly lower than that of the control group. (* p < 0.0001)
Fig. 3Time until cough reflex in controls and patients with and without AP. The time until cough reflex was significantly longer in groups A (without AP) and B (with AP) than in the control group (A: p < 0.001, B: p < 0.001), but there was no significant difference between groups A and B (p = 0.0907)